We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Rheumatology

Rheumatology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

ESTIVAL Trial: Auricular Vagus Nerve Stimulation for Erosive Hand Osteoarthritis Falls Short of Primary Endpoint but Shows Signals in Inflammatory Subgroups
newsneuromodulationrheumatology

ESTIVAL Trial: Auricular Vagus Nerve Stimulation for Erosive Hand Osteoarthritis Falls Short of Primary Endpoint but Shows Signals in Inflammatory Subgroups

By MedXY|Feb 19, 2026

The ESTIVAL trial investigated transcutaneous auricular vagus nerve stimulation (taVNS) for erosive hand osteoarthritis. While the primary pain reduction endpoint was not met, the therapy proved safe and showed potential efficacy in patient

Rapid Remission and Low Disease Activity: Real-World Evidence for Anifrolumab in Systemic Lupus Erythematosus
Internal Medicineanifrolumab

Rapid Remission and Low Disease Activity: Real-World Evidence for Anifrolumab in Systemic Lupus Erythematosus

By MedXY|Feb 17, 2026

Interim data from the multicentre REVEAL study demonstrate that anifrolumab facilitates rapid disease control in real-world SLE patients, with 66% achieving low disease activity within six months, particularly in those with mucocutaneous an

Recombinant Herpes Zoster Vaccine Demonstrates Safety and Non-Inferiority in Patients with Autoimmune Rheumatic Diseases
Infectious Diseasesimmunosuppressionrheumatology

Recombinant Herpes Zoster Vaccine Demonstrates Safety and Non-Inferiority in Patients with Autoimmune Rheumatic Diseases

By MedXY|Feb 15, 2026

A phase 4 RCT in Brazil confirms that the recombinant zoster vaccine does not increase the risk of disease flares in patients with autoimmune rheumatic diseases compared to placebo, maintaining a favorable safety profile even under immunosu

The Tart Cherry Revolution: A Deep Dive into the Science of Longevity, Recovery, and Restorative Sleep
Family Medicine & Nutritionanthocyaninsinflammation

The Tart Cherry Revolution: A Deep Dive into the Science of Longevity, Recovery, and Restorative Sleep

By MedXY|Feb 7, 2026

This article explores the multi-faceted health benefits of tart cherry juice, from its potent anti-inflammatory properties to its role in enhancing sleep and cardiovascular health, supported by the latest clinical research.

Optimizing Value in Fibromyalgia Care: High-Dose Duloxetine and Pregabalin Outperform Amitriptyline in Lifetime Cost-Effectiveness Models
newsfibromyalgiaPharmacoeconomics

Optimizing Value in Fibromyalgia Care: High-Dose Duloxetine and Pregabalin Outperform Amitriptyline in Lifetime Cost-Effectiveness Models

By MedXY|Feb 6, 2026

A recent decision analytical model identifies duloxetine 120 mg as the most cost-effective treatment for moderate-to-severe fibromyalgia, providing superior clinical outcomes at a marginal cost increase compared to amitriptyline, particular

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial
newsBaricitinibbiomarkers

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial

By MedXY|Jan 13, 2026

A post-hoc analysis of the Phase 3 JUVE-BASIS trial identifies key serum biomarkers, including CCL7, CCL18, and IL-6, that correlate with clinical response to baricitinib in JIA, suggesting potential pathways for personalized JAK inhibitor

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
DermatologyGolimumabmethotrexate

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

By MedXY|Jan 13, 2026

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, high

Cognitive Functional Therapy Achieves Unprecedented 3-Year Outcomes for Chronic Disabling Low Back Pain
newsChronic Pain ManagementCognitive functional therapy

Cognitive Functional Therapy Achieves Unprecedented 3-Year Outcomes for Chronic Disabling Low Back Pain

By MedXY|Jan 13, 2026

The RESTORE trial’s 3-year follow-up reveals that Cognitive Functional Therapy (CFT) provides sustained reductions in disability and pain for chronic low back pain compared to usual care, offering a transformative, evidence-based appr

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis
newsclinical trialCost-Effectiveness

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis

By MedXY|Jan 13, 2026

The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its hi

The Rising Burden of Sarcoidosis in England: New Evidence of Increasing Incidence and Significant Mortality Gaps
newsepidemiologyMortality

The Rising Burden of Sarcoidosis in England: New Evidence of Increasing Incidence and Significant Mortality Gaps

By MedXY|Jan 7, 2026

A landmark study of over 18,000 patients reveals that sarcoidosis incidence and prevalence in England are rising, particularly among older adults. With a 36% higher mortality risk compared to the general population, these findings demand a

Rethinking the Knee: Can Targeting the ‘Hoffa’s Fat Pad’ Change the Future of Osteoarthritis Treatment?
newscorticosteroidsknee osteoarthritis

Rethinking the Knee: Can Targeting the ‘Hoffa’s Fat Pad’ Change the Future of Osteoarthritis Treatment?

By MedXY|Jan 6, 2026

A groundbreaking clinical trial explores whether injecting steroids into the knee’s infrapatellar fat pad can alleviate pain and protect cartilage. While primary pain targets weren’t met, the secondary findings offer a fascinating gli

Pentosan Polysulfate Maculopathy Following Subcutaneous Injections for Arthritis: A Case Series
newscase reportdiagnosis

Pentosan Polysulfate Maculopathy Following Subcutaneous Injections for Arthritis: A Case Series

By MedXY|Dec 26, 2025

Three cases of pentosan polysulfate maculopathy occurred after subcutaneous administration for arthritis at much lower cumulative doses than oral use, highlighting retinal toxicity risk and need for early detection.

AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases
AIartificial intelligencecardiovascular risk

AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases

By MedXY|Dec 25, 2025

AI-driven analysis of routine chest CTs reveals that coronary artery calcium is highly prevalent and strongly predictive of MACE and mortality in patients with IMIDs, identifying a critical treatment gap in this high-risk population.

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial
NeurologyChất ức chế BTKfenebrutinib

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial

By MedXY|Dec 23, 2025

The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w

Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression
newspre-eclampsiarheumatology

Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression

By MedXY|Dec 19, 2025

The French GR2 prospective study reveals that while 91% of pregnancies in systemic sclerosis result in livebirths, patients face significantly higher risks of pre-eclampsia, fetal growth restriction, and severe postpartum hemorrhage, with n

Internal MedicineJAK inhibitorsmuscle wasting

Tofacitinib Reverses Muscle Loss in Rheumatoid Arthritis: Insights from the RAMUS Trial

By MedXY|Dec 19, 2025

The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeu

Internal MedicineJAK inhibitorsmuscle wasting

Tofacitinib and Muscle Volume: A Potential Paradigm Shift in Managing Rheumatoid Cachexia

By MedXY|Dec 19, 2025

The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating mus

Digital Psychological Intervention Reduces Distress and Improves Quality of Life in Inflammatory Rheumatic Diseases: Results from a Pilot RCT
AIinflammatory rheumatic diseasesrheumatology

Digital Psychological Intervention Reduces Distress and Improves Quality of Life in Inflammatory Rheumatic Diseases: Results from a Pilot RCT

By MedXY|Dec 14, 2025

A 102-participant pilot RCT in Germany found that a self-guided digital psychological intervention produced clinically meaningful reductions in psychological distress and modest improvements in quality of life at 3 months in people with inf

Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective
NeurologyDisease-Modifying Therapymultiple sclerosis

Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective

By MedXY|Dec 11, 2025

A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r

History of Thrombosis and Hematologic Disease Double the Risk of New Clots in Persistently aPL‑Positive Patients: Prospective APS ACTION Registry Analysis
newsantiphospholipid syndromethrombosis risk

History of Thrombosis and Hematologic Disease Double the Risk of New Clots in Persistently aPL‑Positive Patients: Prospective APS ACTION Registry Analysis

By MedXY|Dec 5, 2025

In 1,067 persistently antiphospholipid antibody–positive patients followed for 4,727 person‑years, prior thrombosis and coexistent hematologic disease each conferred ~2‑fold increased risk for new thrombosis; microvascular disease and obesi

Prev
3 / 7
12345…7
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Browse by specialty

Open language-specific specialty feeds and department pages.

news7286 articlesCardiology1448 articlesClinical Updates1367 articlesOncology1248 articlesDiabetes & Endocrinology924 articlesNeurology883 articlesPublic Health635 articlesGastroenterology618 articles
Hematology-Oncology
559 articles
Pediatrics533 articles
Internal Medicine483 articles